Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary Malignancies

Keyphrases

• Clinical Evaluation 100%
• Liposomal 100%
• Aerosolized 100%
• Nitro 100%
• Camptothecin 100%
• Pulmonary Malignancy 100%
• Primary Lung Cancer 40%
• 9-Nitrocamptothecin 40%
• Aerosol Administration 40%
• Cough 20%
• Dose-limiting Toxicity 20%
• Phase I Study 20%
• Anorexia 20%
• Anemia 20%
• Nausea-vomiting 20%
• Neutropenia 20%
• Phase II Trial 20%
• In(III) 20%
• Partial Remission 20%
• Consecutive Days 20%
• Toxic Effects 20%
• Dose Reduction 20%
• Irritation 20%
• Uterine Cancer 20%
• Forced Expiratory Volume in 1 Second (FEV1) 20%
• Aerosol 20%
• Recommended Dose 20%
• Treatment Schedule 20%
• Skin Rash 20%
• Lipid-based Formulation 20%
• Topoisomerase Inhibitors 20%
• Sterile Water 20%
• Metastatic Lung Cancer 20%
• Daily Treatment 20%
• Face Mask 20%
• Pharyngitis 20%
• Nebulizer 20%
• Patient Plasma 20%
• Treatment Start 20%

Medicine and Dentistry

• Cancer 100%
• Clinical Trial 100%
• Camptothecin 100%
• Lung Cancer 40%
• Rubitecan 40%
• Coughing 20%
• Phase II Trials 20%
• Neutropenia 20%
• Nausea 20%
• Drug Dose Reduction 20%
• Anorexia 20%
• Anemia 20%
• Uterine Cancer 20%
• Liposome 20%
• Forced Expiratory Volume 20%
• Exanthem 20%
• Recommended Drug Dose 20%
• Topoisomerase Inhibitor 20%
• Sterile Water 20%
• Pharyngitis 20%
• Nebulizer 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Camptothecin 100%
• Lung Cancer 40%
• Rubitecan 40%
• Anorexia 20%
• Neutropenia 20%
• Nausea 20%
• Rash 20%
• Anemia 20%
• Phase II Trials 20%
• Remission 20%
• Liposome 20%
• Uterus Cancer 20%
• Coughing 20%
• Sterile Water 20%
• DNA Topoisomerase Inhibitor 20%
• Pharyngitis 20%
• Nebulizer 20%